Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study

Author(s): Dhanya Jose*, Nitin Dhupdale, Jagadish A. Cacodcar and Umesh Kamat

Volume 18, Issue 4, 2023

Published on: 23 September, 2022

Page: [516 - 527] Pages: 12

DOI: 10.2174/1574886317666220803104438

Price: $65

Abstract

Background: COVISHIELD, ChAdOx1 nCoV- 19 Corona Virus Vaccine was granted emergency use authorization (EUA) as the first vaccine in India in January 2021. Knowing what to anticipate after vaccination will reduce vaccine hesitancy in the public. This study aimed to identify and measure the adverse events following COVID-19 vaccination.

Materials and Methods: A cross-sectional observational study was conducted at Goa Medical College, starting on February 21 till May 23, 2021. A total of 418 people were enrolled. We collected the data using the Microsoft Form and analyzed using Microsoft Excel and R-program.

Results: Of the 418 vaccine recipients, the incidence rate of AEFI (Adverse Events Following Immunization) was 54.31%. Fever, fatigue, and headache were the most commonly reported systemic AEFIs. Among these, 54.7% of AEFI were mild, 42.38% were of the moderate category, and only 2.96% were of grade 3 severity. None of the AEFIs were severe enough for hospitalization. Most of them developed symptoms within 24 hours of the first dose. Complete recovery from AEFIs took a median time of 24 hours.

Conclusion: Most of our study findings were consistent with the phase 1, 2/3 trials findings of Oxford-AstraZeneca's ChAdOx1 vaccine. The AEFI symptoms were considered immune reactions to the vaccine. The AEFIs were more common among younger individuals and females. The chance of missing a serious adverse event like a thromboembolic phenomenon cannot be ruled out. We observed low AEFI rates with COVISHIELD in the Indian population compared to Oxford- AstraZeneca's ChAdOx1 vaccine in the UK-based population, which can be explained by preexisting immunity against adenovirus in the Indian population. However, based on the study findings, we may interpret that the COVISHIELD, Serum Institute of India, carries a good safety profile overall.

Keywords: COVISHIELD, adverse events, health care workers, non-serious, serious, ChAdOx1 nCoV-19.

« Previous Next »
Graphical Abstract

[1]
Ministry of Health & Family Welfare. MoHFW | Home. Available from: https://www.mohfw.gov.in/
[2]
Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol 2020; 20(8): 451-2.
[http://dx.doi.org/10.1038/s41577-020-0372-8] [PMID: 32555401]
[3]
WHO. MODULE 3 – Classification of AEFIs - WHO Vaccine Safety Basics. Available from: https://vaccine-safety-training.org/classification-of-aefis.html
[4]
Hervé C, Laupèze B, Del GG, Didierlaurent AM, Tavares SF. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines 2019; 4(1): 39.
[http://dx.doi.org/10.1038/s41541-019-0132-6] [PMID: 31583123]
[5]
Dey A, Wang H, Quinn H, et al. Surveillance of adverse events following immunisation in Australia: Annual report, 2018. Commun Dis Intell 2020; 44: 44.
[http://dx.doi.org/10.33321/cdi.2020.44.12] [PMID: 32178607]
[6]
Council for International Organizations of Medical Sciences, Working Group VIII. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Geneva: CIOMS 2010.
[7]
Jayadevan R, Shenoy RTsA. Survey of symptoms following COVID-19 vaccination in India. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.02.08.21251366]
[8]
Serum Institute of India Pvt. Ltd. Covishield. ChAdOx1 nCoV-19 corona virus vaccine recombinant COVISHIELD.
[9]
Ramasamy MN, Angela M, Ewer KJ, Flaxman AL, Folegatti PM. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396(10267): 1979-93. Available from: https://reader.elsevier.com/reader/sd/pii/S0140673620324661?token=4992171031C3309A79CAD259EED9D20F1B11AF76BE54419D70AE12112312E58CCBB7B043D443B5475EBD37FD57D0960E&originRegion=eu-west-1&originCreation=20210918112526
[10]
Daniel WW. Biostatistics: a foundation for analysis in the health sciences. Biostat Found Anal Health Sci. (7th ed..). N.Y.: John Wiley Sons: New Jersy 1999; pp. 334-9.
[11]
Nigel Lindemann. What’s the average survey response rate? Survey Anyplace. 2021. Available from: https://surveyanyplace.com/blog/average-survey-response-rate/
[12]
Kamal D, Thakur V, Nath N, Malhotra T, Gupta A, Batlish R. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study. Med J Armed Forces India 2021; 77 (Suppl. 2): S283-8.
[http://dx.doi.org/10.1016/j.mjafi.2021.06.014] [PMID: 34334895]
[13]
Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021; 384(19): 1824-35.
[http://dx.doi.org/10.1056/NEJMoa2034201] [PMID: 33440088]
[14]
Kaur U, Ojha B, Pathak BK, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine 2021; 38: 101038.
[http://dx.doi.org/10.1016/j.eclinm.2021.101038] [PMID: 34505032]
[15]
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396(10249): 467-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31604-4] [PMID: 32702298]
[16]
Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands | SpringerLink. 2022. Available from: https://link.springer.com/article/10.1007/s40264-022-01151-w
[17]
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396(10249): 479-88.
[http://dx.doi.org/10.1016/S0140-6736(20)31605-6] [PMID: 32702299]
[18]
Fausther BH, Kobinger GP. Pre-existing immunity against Ad vectors. Hum Vaccin Immunother 2014; 10(10): 2875-84.
[http://dx.doi.org/10.4161/hv.29594] [PMID: 25483662]
[19]
Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol 2010; 82(3): 407-14.
[http://dx.doi.org/10.1002/jmv.21721] [PMID: 20087930]
[20]
Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat Rev Immunol 2020; 20(11): 709-13.
[http://dx.doi.org/10.1038/s41577-020-00460-4] [PMID: 33024281]
[21]
Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun 2020; 11(1): 5749.
[http://dx.doi.org/10.1038/s41467-020-19478-2] [PMID: 33184277]

Rights & Permissions Print Cite
Article Metrics
33
2
© 2024 Bentham Science Publishers | Privacy Policy